Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment
Sponsor: AHS Cancer Control Alberta
Terminated
Insufficient accrual and no funding
Other terminated trials from AHS Cancer Control Alberta
This observational or N/A phase trial investigates Colon Cancer and is currently terminated or withdrawn. AHS Cancer Control Alberta leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Aug 2019 — Jan 2021 [monthly]
Terminated
Status: Unknown Status → Terminated
-
Feb 2019 — Aug 2019 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AHS Cancer Control Alberta
For direct contact, visit the study record on ClinicalTrials.gov .